Cytek Biosciences, Inc.
DE ˙ DB ˙ US23285D1090
3,48 € ↑0,12 (3,57%)
2026-05-29
DEL PRIS
SecurityDE:8EQ / Cytek Biosciences, Inc.
InstitutionPrudential Financial Inc
Latest Disclosed Ownership117,597 shares
Latest Disclosed Value $ 513,899
Prudential Financial Inc reports 10.05% increase in ownership of 8EQ / Cytek Biosciences, Inc.

On May 13, 2026 - Prudential Financial Inc filed a 13F-HR form disclosing ownership of 117,597 shares of Cytek Biosciences, Inc. (DE:8EQ) valued at $435,109 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 106,857 shares of Cytek Biosciences, Inc.. This represents a change in shares of 10.05% during the quarter. The current value of the position is $409,238 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F CYTEK BIOSCIENCES COM 23285D109 117,597 10,740 10.05 514 -4.82 0.0004
2026-02-13 2025-12-31 13F CYTEK BIOSCIENCES COM 23285D109 106,857 -5,810 -5.16 540 38.21 0.0007
2025-11-13 2025-09-30 13F CYTEK BIOSCIENCES COM 23285D109 112,667 0 0.00 391 1.83 0.0005
2025-08-12 2025-06-30 13F CYTEK BIOSCIENCES COM 23285D109 112,667 6,285 5.91 383 -10.09 0.0005
2025-05-13 2025-03-31 13F CYTEK BIOSCIENCES COM 23285D109 106,382 -67,000 -38.64 427 -62.13 0.0006
2025-02-11 2024-12-31 13F CYTEK BIOSCIENCES COM 23285D109 173,382 63,600 57.93 1,125 85.03 0.0015
2024-11-14 2024-09-30 13F CYTEK BIOSCIENCES COM 23285D109 109,782 6,700 6.50 608 5.74 0.0009
2024-08-13 2024-06-30 13F CYTEK BIOSCIENCES COM 23285D109 103,082 -9,150 -8.15 575 -23.64 0.0009
2024-05-14 2024-03-31 13F CYTEK BIOSCIENCES COM 23285D109 112,232 -1,345 -1.18 753 -27.25 0.0011
2024-02-13 2023-12-31 13F CYTEK BIOSCIENCES COM 23285D109 113,577 -2,610 -2.25 1,036 61.47 0.0016
2023-11-13 2023-09-30 13F CYTEK BIOSCIENCES COM 23285D109 116,187 16,000 15.97 641 -25.03 0.0010
2023-08-11 2023-06-30 13F CYTEK BIOSCIENCES COM 23285D109 100,187 100,187 856 0.0012
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.